The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors :: Leach, M. O.
Brindle, K. M.
Evelhoch, J. L.
Griffiths, J. R.
Horsman, M. R.
Jackson, A.
Jayson, G. C.
Judson, I. R.
Knopp, M. V.
Maxwell, R. J.
McIntyre, D.
Padhani, A. R.
Price, P.
Rathbone, R.
Rustin, G. J.
Tofts, P. S.
Tozer, G. M.
Vennart, W.
Waterton, J. C.
Williams, S. R.
Source :: British Journal of Cancer; 5/9/2005, Vol. 92 Issue 9, p1599-1610, 12p
Publication Year :: 2005
Abstract: Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.British Journal of Cancer (2005) 92, 1599-1610. doi:10.1038/sj.bjc.6602550 www.bjcancer.com [ABSTRACT FROM AUTHOR]

Subjects :: MAGNETIC resonance imaging of cancer
MEDICAL research
DIAGNOSTIC imaging
ATOMS
MEDICAL experimentation on humans
MAGNETIC resonance imaging

Full Text Access

Tools